Clinical trial · Observational
Intravenous Chemotherapy and Plant-based Dietary Supplements
Mono-centric, Prospective, Non-Interventional Study of Quantitative and Qualitative Analysis of Dietary Supplement Taken With Chemotherapy Treatments in Patients With Adjuvant Breast Cancer Taken Care of at the Day Hospital
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
More and more patients report taking dietary supplements based on herbal medicine, aromatherapy, vitamintherapy,... in the course of their detoxifying anticancer chemotherapy, to stimulate the immune defenses, to relieve and/or decrease the side effects of chemo or even to act against cancer. At European level, there are between 15 and 73% of patients treated for cancer taking a dietary supplement (in particular phytotherapy) or a great heterogeneity according to the studies. However, there is still little evidence of the efficacy of these dietary supplements. A large proportion of patients do not seem to inform their doctor about the use of dietary supplements. Patients using dietary supplements most often ignore the mode of action of these products and generally say they are not informed. In 2015, at the West Cancerology Institute (ICO), 5 patient files were analyzed taking this type of treatment in addition to chemotherapy; in 2016, 24 files; 2017, 61 patient records and this continues to progress. At the same time, a product appears very frequently associated with cancer chemotherapy: Desmodium Adscendens, an African plant with in vitro properties of liver protector. The Desmodium contains triterpene saponins, alkaloids, flavonoids, polyphenols, and tryptamine derivatives. Morevover, several situations of patients undergoing chemotherapy and taking long-term Desmodium, with hepatic cytolyses were experienced, not explained by the usual treatments (case described in the literature). Therefore, this study will evaluate these new therapeutic modalities that are included in the intake of chemotherapy in order to better know them to improve the therapeutic taking of patients and to focus on the impact of Desmodium in association with chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| dietary supplements questionary | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- dietary supplements group
- description
- dietary supplements questionary
- interventionNames
- Other: dietary supplements questionary
Primary outcomes (1)
- measure
- evaluate quantitatively the use of dietary supplements in patients during IV chemotherapy
- timeFrame
- 12 months
- description
- rate of patients taking a dietary supplement
Secondary outcomes (2)
- measure
- Evaluate the impact of taking Desmodium between the first and last cycle of treatment
- timeFrame
- 12 months
- description
- % of patients with hepatic cytolysis undergoing chemotherapy between the first and last treatments
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * breast cancer treated by intra-venous chemotherapy * inclusion at the last cycle (cure) * all chemotherapy cycles realised at ICO Exclusion Criteria: * no breast cancer * metastatic breast cancer * not all chemotherapy cycles realised at ICO * patient who has not finished his chemotherapy
References
Publications (0)
Data not yet available